SUN PHARMACEUTICAL IND L vs Syschem (India) Ltd

A side-by-side comparison of SUN PHARMACEUTICAL IND L (SUNPHARMA) and Syschem (India) Ltd (SYSCHEM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads SUNPHARMA vs SYSCHEM on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability40
  • Growth02
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

SUNPHARMA takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

39.69
P/E ratio
290.00
20.07
P/B ratio
1.19
0.84%
Dividend yield
0.00%
₹47.84
EPS
₹0.11

Profitability

SUNPHARMA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.00%
Return on equity
10.20%
21.00%
Return on capital
1.00%
30.00%
EBITDA margin
1.20%
19.69%
Net margin
0.00%

Growth

SYSCHEM takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.03%
Revenue CAGR (3Y)
71.37%
10.57%
Profit CAGR (3Y)
43.55%

Size & financial health

SUNPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹4.56L Cr
Market cap
₹164 Cr
₹58,462 Cr
Revenue
₹332 Cr
₹11,509 Cr
Net profit
₹0 Cr
0.61
Debt / equity
0.00
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Syschem (India) Ltd
  • + ["Company is almost debt free.", "Company is expected to give good quarter", "Company has delivered good profit growth of 32.4% CAGR over last 5 years", "Promoter holding has increased by 2.52% over last quarter.", "Company's median sales growth is 70.0% of last 10 years", "Company's working capital requirements have reduced from 40.8 days to 29.3 days"]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 6.41% over last 3 years.", "Contingent liabilities of Rs.50.2 Cr."]
SUN PHARMACEUTICAL IND L full analysis Syschem (India) Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.